Financial Data and Key Metrics Changes - For Q1 of fiscal 2026, total revenue was $120.9 million, a slight increase of $1 million or 0.8% from $119.9 million in Q1 of fiscal 2025, primarily driven by increased DSA revenue and partially offset by decreased RMS revenue [12][19] - DSA revenue increased to $48 million from $42.8 million, reflecting a year-over-year growth of 12%, with discovery pharmacology service and surgical services contributing significantly [5][12] - RMS revenue for Q1 of fiscal 2026 was $72.9 million, a decrease of $4.1 million or 5.4% compared to the prior year, primarily due to lower NHP volumes sold [14][15] - The overall operating loss increased to $16.3 million from $15.5 million in the prior year, driven by an increase in RMS operating loss [16][19] - Consolidated net loss totaled $28.4 million or $0.83 loss per diluted share, compared to a net loss of $27.6 million or $1.02 loss per diluted share in Q1 of fiscal 2025 [18][19] Business Line Data and Key Metrics Changes - DSA business saw strong growth with net new awards of $53.6 million, a 27% increase over Q1 of fiscal 2025, and a 34% year-over-year increase for the trailing twelve-month period [13][19] - DSA margins improved, with non-GAAP operating income for the DSA segment at $8.2 million or 6.8% of total revenue, compared to $7.1 million or 5.9% in the prior year [17] - RMS segment reported non-GAAP operating income of $7.2 million or 5.9% of total revenue, down from $9.4 million or 7.9% in the prior year, primarily due to lower NHP volume sales [18] Market Data and Key Metrics Changes - The book-to-bill ratio for DSA in Q1 of fiscal 2026 was 1.16 to 1, with a trailing twelve-month book-to-bill ratio of 1.08 to 1, indicating a healthy order intake relative to revenue [6][14] - DSA backlog increased to $145.4 million at December 31, 2025, compared to $138.2 million at September 30, 2025, and $130.4 million at December 31, 2024 [14] Company Strategy and Development Direction - The company is focused on improving revenue and margins in the DSA business while reducing costs and diversifying revenue sources in the RMS business [10][11] - The company is enhancing its NAM strategy to support FDA guidance and industry expectations for innovation, with recent collaborations aimed at integrating advanced machine learning tools [10][50] - The site optimization plan is expected to improve margins in future periods, with the current phase set to complete by Q3 of fiscal 2026 [7][9] Management Comments on Operating Environment and Future Outlook - Management expressed optimism about the DSA business's momentum and the ongoing site optimization and cost reduction initiatives in the RMS business [9][10] - The company is navigating macroeconomic factors affecting the RMS business and remains committed to refinancing its debt and improving its balance sheet [9][20] - Management noted that while the first quarter typically experiences seasonality challenges, they expect to see improvements in margins and revenue in the latter half of the fiscal year [26][28] Other Important Information - The company has received a waiver for non-compliance with financial covenant ratios under its credit agreement for Q1 of fiscal 2026 [9] - Capital expenditures in Q1 of 2026 were $5.2 million, with expectations for annual CapEx to remain below 4% of revenue [21][22] Q&A Session Summary Question: Can you provide more details on profitability and adjusted EBITDA trends? - Management acknowledged that margins in RMS impacted adjusted EBITDA, with some operational expenses higher than expected, and indicated that seasonality will likely follow previous patterns [25][26] Question: What is driving the positive trend in DSA awards? - Management attributed the growth in DSA awards to improved customer relationships, increased sales force efforts, and scientific strengths within the company [29][31] Question: What is the outlook for RMS operating leverage? - Management indicated that reduced NHP volumes overshadowed operating leverage benefits, but cost reductions from facility closures will contribute positively in future quarters [40][42] Question: How much was NHP volume down year-over-year? - Management reported that NHP volumes were down approximately 25% year-over-year [44][45] Question: Can you elaborate on new relationships in the NAM space? - Management highlighted ongoing R&D efforts and collaborations aimed at innovation, which are expected to drive incremental revenues [49][50]

monday.com (NasdaqGS:MNDY) Q4 2025 Earnings call February 09, 2026 08:30 AM ET Company ParticipantsByron Stephen - VP of Investor RelationsCasey George - CROEliran Glazer - CFOEran Zinman - Co-Founder and Co-CEOMark Murphy - Head of Software ResearchRoy Mann - Co-Founder and Co-CEOConference Call ParticipantsAlex Zukin - Managing Director and Senior AnalystAllan Verkhovski - Director and Application Software AnalystArjun Bhatia - Partner and Equity Research AnalystBilly Fitzsimmons - Senior Research Analyst ...

Financial Data and Key Metrics Changes - Total shipments in Q4 were 3.8 million tons, slightly lower than Q3 due to seasonal impacts, with expectations for Q1 to improve back to 4 million tons [17] - Q4 price realization was $993 per net ton, down by around $40 per net ton, but a substantial improvement in realized prices is expected starting in Q1 2026, with an anticipated increase of approximately $60 per ton [18] - 2025 marked the third consecutive year of unit cost reductions, with a reduction of $40 per ton, and expectations for another $10 per ton decrease in 2026 [19] Business Line Data and Key Metrics Changes - The company has secured more business from automotive clients, which is expected to show throughout 2026 as OEMs reshore production back to the U.S. [4] - The cancellation of the slab contract with ArcelorMittal is projected to yield an EBITDA improvement of around $500 million by replacing lower-margin slabs with higher-margin products [28][29] - The company anticipates continued demand for domestically produced slabs due to melted and poured requirements [5] Market Data and Key Metrics Changes - The Canadian government has moved to restrict imported steel, creating positive momentum for the company's Canadian subsidiary, Stelco [4] - The spot steel price is currently at a two-year high, benefiting the company due to its cost structure and ability to generate its own power [6] - Vehicle production in the U.S. was down for three consecutive years, but a return to pre-COVID levels is expected due to policy-driven reshoring [7] Company Strategy and Development Direction - The company is focused on sustainable performance in an improved market, operating with a leaner footprint and a stronger order book [24] - The partnership with POSCO is a strategic priority, aimed at enhancing industrial cooperation and meeting U.S. trade requirements [14][52] - The company is positioned to benefit from the transition from aluminum to steel in automotive applications, leveraging existing technology and production capabilities [10][54] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the improving business environment, with solid order books, rising prices, and declining costs [23] - The company is confident in its ability to absorb increased automotive demand with existing production capacity, avoiding the need for new plant construction [8] - Management highlighted the importance of the recent changes in the Canadian steel market and the positive impact on pricing and shipments [12][63] Other Important Information - The company achieved the lowest total recordable incident rate since becoming a steel producer, with a 43% improvement compared to 2021 [15] - Capital expenditures in 2025 were at a record low of $561 million, with projections for 2026 to be around $700 million [20] - Total liquidity at the end of 2025 was $3.3 billion, with a focus on generating EBITDA and cash flow [22] Q&A Session Summary Question: What benefit is expected from the cancellation of the slab contract? - The cancellation is projected to yield an EBITDA improvement of around $500 million by replacing lower-margin slabs with higher-margin products [28][29] Question: When should the improvement in EBITDA be expected? - The company is already selling the material in Q1, with more impact expected in Q2 and Q3 as cost flows through inventory [32] Question: How much open capacity is available for contracting? - The company has downstream capacity in every location, with significant potential to deploy more specialized steel products [40][41] Question: What is the outlook for Q1 regarding ASP and costs? - Shipments are expected to return to 4 million tons, with ASP projected to increase by $60 per ton in Q1, while costs may rise temporarily before normalizing [44][46] Question: How has Stelco performed and what is the outlook? - Stelco was disappointing in 2025 but is expected to contribute significantly in 2026 as market dynamics improve [60][62] Question: What is the status of asset sales? - The company is under contract to sell several idled properties, with total proceeds expected to reach $425 million, while larger asset sales are on hold pending POSCO negotiations [70][72]

Financial Data and Key Metrics Changes - Service revenue grew 11% year-over-year, now representing 80% of total revenue [6][22] - Total revenue increased 7% year-over-year, with an adjusted growth of 9% when accounting for prior year accelerated product revenue [6][23] - Adjusted EBITDA increased 26% year-over-year, with margins expanding by 4% to 23% [7][24] - Net debt to Adjusted EBITDA improved to 2.7 times, with expectations to decline to around 2.4 times by year-end [7][25] Business Line Data and Key Metrics Changes - The company is focused on high-margin recurring SaaS revenue, with services revenue now accounting for 80% of total revenue, up from 77% in the prior year [22][23] - Adjusted EBITDA gross margins remained stable at 67%, with product margins steady in the low 30% range [24] Market Data and Key Metrics Changes - The company secured a significant South African public sector contract, expected to generate substantial recurring SaaS and services revenue over a multi-year term [8][9] - The AI video pipeline increased 71% sequentially, indicating strong demand for advanced safety and compliance solutions [11] Company Strategy and Development Direction - The company aims for a Q4 exit run rate for FY26 of 10% total revenue growth and over 10% growth in recurring revenue [4][5] - The focus is on expanding partnerships with Tier 1 customers and enhancing the Unity platform's capabilities [10][14] - The Data Highway strategy aims to connect fragmented data across enterprises, enabling operational decisions and safety outcomes [15][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving growth milestones, indicating a positive outlook for FY27 [5][21] - The business environment is improving, with a focus on creating tangible ROI for customers [41][42] - Management highlighted the importance of AI as an enabler for the industry, enhancing data utilization and operational efficiency [35][36] Other Important Information - The company is maintaining operating expense investments to support growth, with an updated Adjusted EBITDA guidance of approximately 45% annual growth [25] - Initial investments for the South African contract will focus on personnel, processes, and systems to support scalability [55][56] Q&A Session Summary Question: Growth mix and contribution of new logos versus upsell - Management indicated that 65%-70% of business comes from existing customers, with 30% from new logos, including the South African government contract [31] Question: Business environment comparison to six months ago - Management noted that the business environment is improving, with increased enterprise business and repeat business from satisfied customers [40][41] Question: Update on AT&T reps training and South Africa contract revenue - Management refrained from providing specific financial details but indicated that the contract aligns with existing ARPU and margin expectations [43] Question: Competitive nature of the South African contract - Management confirmed that the contract was highly competitive, with a focus on robust capabilities and partnerships, particularly with MTN [74]

Financial Data and Key Metrics Changes - The company reported revenue of $3.9 billion for the third quarter, reflecting a 3% increase year-over-year on a reported basis, unchanged in constant currency [15][16] - Adjusted EBITDA decreased by 1% year-over-year to $696 million, while Adjusted Pre-Tax Income grew by 5% year-over-year to $168 million [16][18] - Free cash flow generated in the third quarter was $217 million, with a net CapEx of $210 million [18][19] Business Line Data and Key Metrics Changes - Kyndryl Consult experienced a strong performance with a 20% year-over-year growth in constant currency, now representing 25% of total revenue [15][16] - Hyperscaler-related revenue reached $500 million in the third quarter, marking a 58% increase year-over-year, exceeding initial growth expectations [17] - The company signed contracts totaling $3.9 billion in the quarter, with a trailing 12-month revenue book-to-bill ratio remaining above 1.0 [5][16] Market Data and Key Metrics Changes - The company noted a slowdown in attrition rates, particularly in strategic markets and the UK, which has led to increased local hiring costs [31][32] - The evolving partnership with IBM has resulted in a significant reduction in annualized spend from nearly $4 billion to approximately $2 billion, impacting revenue growth [9][58] Company Strategy and Development Direction - The company is focused on expanding its capabilities in AI and private cloud services, responding to increased demand driven by data sovereignty and security requirements [12][66] - The strategic direction emphasizes the importance of long-term customer relationships and adapting to changing market dynamics [13][66] - The company aims to achieve fiscal 2028 targets, projecting approximately $1.1 billion in Adjusted Pre-Tax Income and over $1 billion in adjusted free cash flow [14][23] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that longer sales cycles and evolving customer consumption models are impacting revenue expectations [24][28] - The company remains confident in its growth strategy despite current challenges, emphasizing the importance of adapting to industry disruptions caused by AI and regulatory changes [7][39] - Management reiterated that they do not expect a restatement of financial statements despite ongoing SEC reviews [25][36] Other Important Information - The company has repurchased 3.7 million shares in the quarter, representing 1.6% of outstanding shares, as part of its capital allocation strategy [18][19] - The financial position remains strong with a cash balance of $1.35 billion and a net leverage ratio of 0.7x Adjusted EBITDA [20][21] Q&A Session Summary Question: Outlook and Revision Factors - Analysts inquired about the reasons behind the revised outlook, focusing on sales cycle delays and the evolving IBM partnership [27][28] - Management explained that the sales cycles have lengthened due to market dynamics and regulatory discussions, impacting growth expectations [28][29] Question: Strategic Market Changes - Questions were raised regarding changes in strategic markets, particularly in the UK, and the associated costs and benefits [30][31] - Management indicated that investments in local markets are necessary but may take time to yield results [31][32] Question: Free Cash Flow and Working Capital - Analysts sought clarification on the factors affecting free cash flow projections, particularly in relation to pre-tax income revisions [49][50] - Management confirmed that the primary driver of the change in free cash flow guidance is linked to the revision in pre-tax income [50] Question: Confidence in Fiscal 2028 Targets - Questions were posed about the building blocks supporting confidence in achieving fiscal 2028 targets despite current shortfalls [56][57] - Management highlighted the importance of cash flow growth, profitability improvements, and the shift towards higher-margin contracts as key factors [58][59]

Kyndryl (NYSE:KD) Q3 2026 Earnings call February 09, 2026 08:30 AM ET Company ParticipantsHarsh Chugh - Interim CFOIan Zaffino - Managing DirectorJames Faucette - Managing DirectorJonathan Lee - Managing DirectorLori Chaitman - Global Head of Investor RelationsMartin Schroeter - Chairman and CEOConference Call ParticipantsJames Friedman - Senior AnalystTien-tsin Huang - Managing Director and Senior AnalystOperatorPlease be advised that today's conference is being recorded. I would now like to hand the confe ...

Waters (NYSE:WAT) Q4 2025 Earnings call February 09, 2026 08:30 AM ET Company ParticipantsAmol Chaubal - SVP and CFOCaspar Tudor - Head of Investor RelationsUdit Batra - President and CEOConference Call ParticipantsCasey Woodring - Research Analyst of Life Science Tools and DiagnosticsCatherine Schulte - Senior Research Analyst and Director, Life Sciences and DiagnosticsDoug Schenkel - Managing Director, Senior Research Analyst and Head of Life Science Tools and DiagnosticsJack Meehan - Equity Research Anal ...

Financial Data and Key Metrics Changes - The cash position at December 31 was $131.7 million with no debt, and the company utilized $7.1 million in operating activities during the quarter [8][9] - Research and development expenses for the quarter were $4.7 million, down from $10.4 million in the same quarter last year, while general and administrative expenses decreased to $2.1 million from $3.1 million [8][9] - The net loss for the quarter was reported at $5.7 million, or $0.06 per share [9] Business Line Data and Key Metrics Changes - The decrease in operating expenses was primarily due to the completion of a large manufacturing campaign for blarcamesine and a reduction in clinical trial activities following the completion of the ANAVEX3-71 phase II study in schizophrenia [9] Market Data and Key Metrics Changes - The company is participating in the ACCESS-AD initiative, a European program aimed at accelerating the adoption of innovative diagnostic and therapeutic approaches for Alzheimer's disease [3][4] Company Strategy and Development Direction - The company is focused on advancing its clinical pipeline, particularly the lead candidate oral blarcamesine for early Alzheimer's disease, and is working with regulatory agencies in Europe and the U.S. to progress this treatment [3][4] - Anavex plans to provide updates on regulatory and clinical trial developments for blarcamesine in other indications, including Parkinson's disease and Fragile X [5][6] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of blarcamesine to improve the lives of patients with neurological disorders and emphasized the importance of scalable treatment options [10] - The company is committed to addressing the unmet needs in Alzheimer's disease and is preparing for a confirmatory study if approved under the conditional marketing authorization [51] Other Important Information - The company is planning to submit data from the phase IIB/III ANAVEX2-73-AD-004 program to the FDA and is working closely with the EMA for the re-examination of the marketing authorization application for blarcamesine [4][5] - New scientific findings related to blarcamesine will be presented at upcoming conferences and publications [6] Q&A Session Summary Question: Can you provide additional information regarding the rapporteur and co-rapporteur for the re-examination of the CHMP opinion on blarcamesine? - The rapporteurs will be selected from the 27 EU countries [15] Question: What is the timeline for the re-examination process? - The re-examination process is expected to last for the first half of the year, involving a 60 + 60 day period for responses and reviews [16] Question: When do you anticipate filing a formal NDA submission with the FDA? - The company plans to advance this once closer to the submission date, following productive discussions with the FDA [17] Question: What additional information will be included in the resubmission to the EMA? - The resubmission will include data from the AD-004 study, A-Clear study population, and correlations of clinical efficacy with brain atrophy reduction [24] Question: Are there any ongoing trials currently? - The only ongoing trials are compassionate use programs for Rett Syndrome and Alzheimer's Disease, with plans for studies in Parkinson's Disease and Fragile X [28] Question: How is blarcamesine involved in the ACCESS-AD program? - Blarcamesine will be evaluated in a placebo-controlled trial as part of the ACCESS-AD initiative, focusing on early Alzheimer's patients [51]

Apollo Global Management (NYSE:APO) Q4 2025 Earnings call February 09, 2026 08:30 AM ET Company ParticipantsJim Zelter - PresidentMarc Rowan - CEOMartin Kelly - CFOMichael Cyprys - Managing DirectorNoah Gunn - Head of Investor RelationsConference Call ParticipantsAlex Blostein - Managing Director and AnalystBen Budish - Director and AnalystBill Katz - AnalystBrennan Hawken - AnalystBrian Bedell - Managing Director and AnalystGlenn Schorr - Managing Director and AnalystJohn Barnidge - Director and AnalystKen ...

Waters (NYSE:WAT) Q4 2025 Earnings call February 09, 2026 08:30 AM ET Company ParticipantsAmol Chaubal - SVP and CFOCaspar Tudor - Head of Investor RelationsUdit Batra - President and CEOConference Call ParticipantsCatherine Schulte - Senior Research Analyst and Director, Life Sciences and DiagnosticsDoug Schenkel - Managing Director, Senior Research Analyst and Head of Life Science Tools and DiagnosticsJack Meehan - Equity Research Analyst, Life Science Tools and DiagnosticsTycho Peterson - Managing Direct ...